Major Breakthroughs in Major Depressive Disorder

All Sessions Will Be Held in Eastern Time (ET)

Historically, hypotheses regarding the neuropathology and treatment of depression have focused on monoaminergic targets (e.g., serotonin and norepinephrine). Our understanding of the biological underpinnings of major depressive disorder (MDD) is rapidly advancing and indicating involvement of non-monoaminergic systems, such as those involving glutamate and orexin. This broadened understanding of MDD has led to discoveries of novel targets and treatment strategies that may improve our ability to effectively and promptly treat patients with MDD or difficult-to-treat depression (DTD).

During this half-day program, an update on our understanding of the neurocircuitry associated with MDD will be provided as well as a discussion of novel and emerging treatment strategies (including rapid-acting and adjunct medications) with promise for improving the lives of patients suffering with MDD or DTD.